| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8580830 | AQUESTIVE | Non-mucoadhesive film dosage forms |
Nov, 2029
(6 years from now) | |
| US9095577 | AQUESTIVE | Stabilized amine-containing actives in oral film compositions |
Jul, 2030
(6 years from now) | |
Zuplenz is owned by Aquestive.
Zuplenz contains Ondansetron.
Zuplenz has a total of 2 drug patents out of which 0 drug patents have expired.
Zuplenz was authorised for market use on 02 July, 2010.
Zuplenz is available in film;oral dosage forms.
The generics of Zuplenz are possible to be released after 13 July, 2030.
Drugs and Companies using ONDANSETRON ingredient
Market Authorisation Date: 02 July, 2010
Treatment: NA
Dosage: FILM;ORAL
More Information on Dosage
ZUPLENZ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic